Clinical studies have shown that approximately 70–80% (depending on the trials) of EGFR mutation-positive NSCLC patients respond to EGFR-TKI treatment19,23–32, and a small proportion (~20–30%) of patients carrying EGFR-activating mutations still do not show objective response when treated with EGFR-TKI. This evidence concerns the gene EGFR and non-small cell lung carcinoma.